Innovent Biologics develops complex, affordable biopharmaceutical products targeting cancer, ophthalmology, autoimmune disorders and cardiovascular diseases. The company has built a large-scale GMP-compliant manufacturing base meeting CFDA, FDA and EMA standards. Its pipeline comprises 16 molecules in research, seven in clinical development (four in Phase III) and one with a BLA submitted to the CFDA. Innovent plans to use new funding to accelerate and expand clinical programs and to build a commercial team. The company was founded in August 2011 by Dr. Michael Yu and operates from Suzhou. It has received national research recognitions and grants for multiple molecules.

Total raised

$150M

Funding rounds

1

Latest round

Series E

Latest activity

Apr 2018